Overview

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.

Phase:

N/A

Details

Lead Sponsor:

Beijing Tsinghua Chang Gung Hospital

Collaborator:

Peking University People's Hospital

Treatments:

Kallikreins